<DOC>
	<DOC>NCT02959190</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as Galcanezumab in Japanese participants with migraine.</brief_summary>
	<brief_title>A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>For Episodic Migraine participants: Participants who completed the treatment period of Galcanezumab study CGAN. Have a diagnosis of chronic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)3 beta guidelines (1.3) (ICHD3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50. For Chronic Migraine participants: Are currently enrolled in or have participated within the last 30 days or within 5 halflives (whichever is longer) in a clinical trial involving an investigational product. Current use or prior exposure to Galcanezumab or other antibodies of CGRP or its receptor. Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to Galcanezumab and the excipients in the investigational product. History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilartype migraine) defined by IHS ICHD3 beta. Failure to respond to 3 or more adequately dosed migraine preventive treatments from different classes (that is, maximum tolerated dose for at least 2 months).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prevention</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>headache</keyword>
</DOC>